bioRxiv Science⌕ Search

Biology subjects

Kigondu, E. M.

Publications and source records attributed to Kigondu, E. M..

3 recordsLinked to original sources

Mycobacteriophage D29-mediated lysis improves recovery of mycobacterial genomic DNA from low-biomass samples

BackgroundDetection of rare mycobacterial genotypes, including those associated with antibiotic resistance or population heterogeneity is important for diagnostic, therapeutic and research applications. This depends on efficient recovery of genomic DNA (gDNA) from sampled populations, a challenging requirement in paucibacillary clinical materials. Mycobacteria have uniquely lipid-rich, structurally robust cell envelopes which resists cell lysis by conventional methods. Here, we characterize mycobacteriophage D29-mediated lysis at the single-cell level, evaluating its utility as a biological lysis strategy for mycobacterial DNA isolation, benchmarked against the standard cetyltrimethylammonium bromide (CTAB) extraction method. MethodsConditions for mycobacteriophage D29 infection of Mycobacterium smegmatis (Msm) were established, and single-cell phage adsorption and phage-mediated lysis visualized through live-cell time-lapse fluorescence microscopy (FM). A mycobacteriophage D29-based lysis method was applied to both Msm and M. tuberculosis (Mtb), and extraction efficiencies compared with the standard CTAB method. Cell lysis efficiency was quantified by colony forming units (CFU), flow cytometry (FC) and FM; DNA yield was determined by quantitative polymerase chain reaction (qPCR) and droplet digital PCR (ddPCR). ResultsMycobacteriophage D29 adsorption was observed at the poles and septa of individual mycobacterial cells. Phage infection was associated with loss of cytoplasmic green fluorescence protein (GFP) reporter protein, with uptake of a cell death marker propidium iodide (PI). Mycobacteriophage D29 infection resulted in a marked loss of cell viability, with >6log10 reduction in CFU, and cell lysis efficiencies calculated as 93.3% (FC) and 96.8% (FM). Molecular quantification (qPCR and ddPCR) indicated that the mycobacteriophage-based lysis achieved between 4- to 7-fold greater gDNA yields in Msm and between 3- to 12-fold greater gDNA yields in Mtb H37Ra compared with the CTAB method. Notably, gDNA extraction efficiencies in both mycobacterial species exceeded 92% in low-biomass samples containing approximately 100, 175 and 320 bacilli. ConclusionThese results demonstrate the utility of the mycobacteriophage D29-based method for improved DNA extraction yields from mycobacteria through direct lysis of individual bacilli, with performance suited to low-biomass samples. SummaryRecovering genomic DNA (gDNA) from low numbers of mycobacteria is a persistent bottleneck for diagnostics and genomic studies, because the lipid-rich mycobacterial envelope resists conventional lysis. Here we show that mycobacteriophage D29 provides an efficient, biologically selective route to mycobacterial DNA. Leveraging single-cell live imaging, we reveal that phage D29 adsorbs preferentially at the poles and septa of individual cells, and that infection is heterogeneous and asynchronous, progressing from envelope permeabilization to loss of viability. Applied as an extraction method and benchmarked against the standard cetyltrimethylammonium bromide (CTAB) protocol, phage D29-mediated lysis recovered 4- to 7-fold more gDNA in Mycobacterium smegmatis (Msm) and 3- to 12-fold more in Mycobacterium tuberculosis (Mtb). Critically, extraction efficiency exceeded 92% in both species in low-biomass samples of approximately 100, 175 and 320 bacilli, where CTAB performed poorly (<20% efficiency). These findings support phage-mediated lysis as a quantitative, near-complete DNA-recovery method that outperforms conventional extraction precisely in the paucibacillary regime of greatest clinical relevance and demonstrate the value of single-cell interrogations in building towards precision tools to engage the mycobacterial cell.

microbiology↗

Natural product-based putative efflux inhibitors restore bedaquiline susceptibility in a drug-resistant Mycobacterium tuberculosis mutant

Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) remains a potent threat to global public health. Moreover, the alarming surge in the number of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mtb strains will continue to imperil TB control efforts. Thus, the discovery of new TB agents with novel modes of action or resistance-reversing therapeutics is a pressing priority. In this study, we report the generation of spontaneous Mtb mutants exhibiting bedaquiline (BDQ) resistance and the subsequent evaluation of natural product-derived efflux inhibitors (EIs) that restored the antimicrobial efficacy of BDQ against the mutants. BDQ-resistant mutants were successfully isolated, and colonies were observed on agar plates with concentrations up to 100x the minimum inhibitory concentration (MIC). Upon screening against BDQ, the resistant strains exhibited MIC values ranging from 0.098 M to 3.136 M, corresponding to 1-32-fold increases relative to the wild type, with higher resistance observed on 50x- and 100x-selection plates. Genetic analysis identified point mutations and frameshifts in key resistance-related genes, including Rv0678, pepQ, and atpE. Notably, combining BDQ with EIs such as berberine (BER), reserpine (RES), piperine (PIP), and lyoniresinol (LYO) remarkably lowered the MIC in the selected mutant strain. Synergistic effects were observed for BDQ+BER (FICI = 0.188; 16-fold MIC reduction) and BDQ+RES (FICI = 0.37; 8-fold MIC reduction). For BDQ+LYO, the FICI could not be calculated because LYO did not have an MIC at the highest concentration tested; however, this combination produced the strongest effect, restoring susceptibility with a 64-fold MIC reduction and exhibiting bactericidal activity. These results highlight the role of efflux pumps in BDQ resistance and support the use of natural product-derived EIs as potential supplementary therapies against drug-resistant Mtb.

microbiology↗

Identification of mycobacterial efflux pump inhibiting compounds from Berberis holstii Engl. and determination of their mechanism of action

Mycobacterium tuberculosis (Mtb), the causative agent for tuberculosis (TB), is the leading infectious killer of humankind. In 2023, an estimated 10.8 million new cases of TB and 1.25 million deaths were reported globally. Sub-Saharan Africa faces a heavy TB burden, worsened by high HIV-AIDS prevalence and rising drug resistance, making novel anti-TB therapies a pressing priority. This study investigated the efflux inhibition (EI) activity of compounds characterised from Berberis holstii Engl. extracts. Following in vitro evaluation of the antimycobacterial activity of aqueous and organic extracts against the non-pathogenic mycobacterial model, Mycobacterium smegmatis (Msm), and Mtb. Thereafter, molecular docking of several compounds identified in chromatographic fractions onto Rv1258c, MmpS5-MmpL5 and Rv2333c Mtb efflux pumps (EPs) was undertaken to infer their binding modes and affinities. Subsequently, fractions containing potentially active compounds were tested in combination with spectinomycin (SPEC) and fractional inhibitory concentration index (FICI) values determined. Validation of Mtb efflux pump inhibition was performed using CRISPRi knockdown strains of Rv1258c and Rv2333c. MeOH extracts of the root and the stem bark, and aqueous extracts of the roots, exhibited minimum inhibitory concentration (MIC99) values of 906.25g/ml, 4500 g/ml and 1875 g/ml, respectively, against wild-type Msm. On the other hand, MeOH extract of the leaves and aqueous extract of the stem bark had MIC99 values of 60.43 g/ml and 1.74 g/ml respectively, against wild-type Mtb. Molecular docking of chillanamine, isoboldine, berberrubine, reticuline, N-methylcoclaurine, thalifoline, apoglaziovine, and orientine onto Mtb Rv1258c, MmpS5-MmpL5 and Rv2333c revealed string binding affinities of <-5 kcal/mol. Of the seven fractions containing the bioactive compounds evaluated in checkerboard assays, six were synergistic with SPEC (FICI <0.5), with two fractions lowering the MIC99 of SPEC by 8-fold against wild-type Mtb. This study identified phytochemicals with probable Mtb efflux pump inhibition, warranting further investigation for potential use in TB combination therapy.

microbiology↗